Loading data for ADCT — first visit, this takes a few seconds.
ADC Therapeutics SA (ADCT)
NYSE: ADCT
· 实时价格 · USD
1.34
+0.02 (1.52%)
收盘价： Sep 09, 2026, 8:00 PM
股价、关键数字和最新消息，都在这一页。
ADC Therapeutics SA（ADCT）股价、分析与数据
暂无数据
| 买价 | 1.33 |
| 市值 | 156M |
| 营收（TTM） | 79.6M |
| 净利润（TTM） | -96.9M |
| 1.85 | |
| -0.54 | |
| n/a | |
| -0.82 | |
| 市净率（TTM） | -0.68 |
| 市销率（TTM） | 1.96 |
| 财报日期 | Nov 10, 2026 |
| 卖价 | 1.34 |
| 成交量 | 326,751 |
| 20日均量 | 1,878,361 |
| 开盘价 | 1.30 |
| 前收盘价 | 1.32 |
| 日内区间 | 1.30 - 1.34 |
| 52周区间 | 0.78 - 4.98 |
| 分析师 | n/a |
| 目标价 | n/a |
| 分红 | n/a |
| 除息日 | n/a |
关于 ADCT
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell l...
公司完整简介财报意外
ADC Therapeutics SA 已于 Aug 13, 2026 发布季度财报：
- 营收为 $20.85M 低于预期 $0, ， -9.47% 同比下滑.
- 每股收益为 -0.11 超出预期 0.11, ， 78.00% 同比增长.
第 1 页，共 2 页